Paper656247
Acid-base balance and neostigmine antagonism of pancuronium neuromuscular blockade.
Miller RD and 1 other. Br J Anaesth, 1978. Cited by 33 papers, by iCite.
Cite this record
ConductScience Library. Acid-base balance and neostigmine antagonism of pancuronium neuromuscular blockade. Papers, record 656247. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/656247
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acid-Base Equilibrium | Major topic |
| Neostigmine | Major topic |
| Neuromuscular Junction | Major topic |
| Pancuronium | Major topic |
| Animals | |
| Cats | |
| Time Factors |
Source PubMed
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41485064 | Sodium ascorbate versus ascorbic acid in sepsis: a narrative review of emerging cardiovascular and neurological benefits. | Crit Care | 2026 | https://conductscience.org/library/papers/41485064 | PubMed |
| 41457243 | A preclinical randomised controlled dose optimization of megadose sodium ascorbate for reversal of gram-negative sepsis-induced cardiovascular, brain and kidney dysfunction. | Crit Care | 2025 | https://conductscience.org/library/papers/41457243 | PubMed |
| 37876602 | LOVIT or leave it: The vitamin C debate continues. | Crit Care Resusc | 2023 | https://conductscience.org/library/papers/37876602 | PubMed |
| 37828547 | Mega-dose sodium ascorbate: a pilot, single-dose, physiological effect, double-blind, randomized, controlled trial. | Crit Care | 2023 | https://conductscience.org/library/papers/37828547 | PubMed |
| 24827571 | Comparative pharmacodynamics of pancuronium, cisatracurium, and CW002 in rabbits. | J Am Assoc Lab Anim Sci | 2014 | https://conductscience.org/library/papers/24827571 | PubMed |
| 9089751 | Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation. | Pharm World Sci | 1997 | https://conductscience.org/library/papers/9089751 | PubMed |
| 6400756 | Neuromuscular blocking drugs. | Can Anaesth Soc J | 1983 | https://conductscience.org/library/papers/6400756 | PubMed |
| 6372957 | Neuromuscular blocking drugs in anaesthesia. | Can Anaesth Soc J | 1984 | https://conductscience.org/library/papers/6372957 | PubMed |
| 2060078 | Monitoring, new drugs, and reversal of neuromuscular blocking drugs. | Can J Anaesth | 1991 | https://conductscience.org/library/papers/2060078 | PubMed |
| 1451224 | The use of muscle relaxants in the intensive care unit. | Can J Anaesth | 1992 | https://conductscience.org/library/papers/1451224 | PubMed |
| 223751 | Recent developments with muscles relaxants and their antagonists. | Can Anaesth Soc J | 1979 | https://conductscience.org/library/papers/223751 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/656247
GET https://conductscience.org/api/papers/v1/656247/authors